Market open
Gyre Therapeutics/$GYRE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Gyre Therapeutics
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Ticker
$GYRE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
593
Website
GYRE Metrics
BasicAdvanced
$903M
-
-$1.17
-
-
Price and volume
Market cap
$903M
52-week high
$26.37
52-week low
$8.26
Average daily volume
147K
Financial strength
Current ratio
3.724
Quick ratio
3.111
Long term debt to equity
1.118
Total debt to equity
1.823
Management effectiveness
Return on equity (TTM)
-85.32%
Valuation
Price to revenue (TTM)
8.188
Price to book
14.28
Price to tangible book (TTM)
14.67
Price to free cash flow (TTM)
-385.475
Growth
Revenue change (TTM)
-9.04%
Earnings per share change (TTM)
-1,737.49%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gyre Therapeutics stock?
Gyre Therapeutics (GYRE) has a market cap of $903M as of January 15, 2025.
What is the P/E ratio for Gyre Therapeutics stock?
The price to earnings (P/E) ratio for Gyre Therapeutics (GYRE) stock is 0 as of January 15, 2025.
Does Gyre Therapeutics stock pay dividends?
No, Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Gyre Therapeutics dividend payment date?
Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Gyre Therapeutics?
Gyre Therapeutics (GYRE) does not currently have a Beta indicator.